Ageing – Pipeline Review, H2 2012

Date: December 26, 2012
Pages: 52
Price:
US$ 2,000.00 US$ 1,800.00
Offer valid until December 31, 2014!
License [?]:
Publisher: Global Markets Direct
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: AFDC2AA478BEN
Leaflet:

Download PDF Leaflet

Ageing – Pipeline Review, H2 2012

Summary

Global Markets Direct’s, 'Ageing - Pipeline Review, H2 2012', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Ageing, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Ageing. Ageing - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope
  • A snapshot of the global therapeutic scenario for Ageing.
  • A review of the Ageing products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • Coverage of products based on various stages of development ranging from discovery till registration stages.
  • A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
  • Coverage of the Ageing pipeline on the basis of route of administration and molecule type.
  • Key discontinued pipeline projects.
  • Latest news and deals relating to the products.
Reasons to buy
  • Identify and understand important and diverse types of therapeutics under development for Ageing.
  • Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
  • Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
  • Devise corrective measures for pipeline projects by understanding Ageing pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
Introduction
Global Markets Direct Report Coverage
Ageing Overview
Therapeutics Development
An Overview of Pipeline Products for Ageing
Ageing Therapeutics under Development by Companies
Ageing Therapeutics under Investigation by Universities/Institutes
Mid Clinical Stage Products
Comparative Analysis
Discovery and Pre-Clinical Stage Products
Comparative Analysis
Ageing Therapeutics – Products under Development by Companies
Ageing Therapeutics – Products under Investigation by Universities/Institutes
Companies Involved in Ageing Therapeutics Development
Novogen Limited
Novocell, Inc.
Bioo Therapeutics
Ageing – Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
NV-07Alpha - Drug Profile
Product Description
Mechanism of Action
R&D Progress
BIOO-4 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
BIOO-7 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
RDC-6 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
RDC-1 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
RDC-2 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
RDC-7 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
CHR-26 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
RDC-8 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
RDC-21 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
RDC-14 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
RDC-19 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
RDC-20 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
RDC-29 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
CHR-1 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
CHR-3 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
CHR-8 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
CRH-9 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
CHR-12 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
CHR-25 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
CHR-50 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
CHR-54 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Ciproxifan - Drug Profile
Product Description
Mechanism of Action
R&D Progress
F-899 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Laminin Peptide YIGSR - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Ageing – Product Development Milestones
Featured News & Press Releases
Aug 15, 2011: Chronos Therapeutics Validates Proprietary Anti-ageing Drug Candidate CHR-50
May 15, 2011: Chronos Therapeutics Validates Proprietary Anti-ageing Drug Candidate CHR-25
Apr 15, 2011: Chronos Therapeutics Validates Proprietary Anti-ageing Drug Candidate CHR-54
Feb 15, 2011: Chronos Therapeutics Validates Proprietary Anti-ageing Drug Candidate CHR-12
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

LIST OF TABLES

Number of Products Under Development for Ageing, H2 2012
Products under Development for Ageing – Comparative Analysis, H2 2012
Number of Products under Development by Companies, H2 2012
Number of Products under Investigation by Universities/Institutes, H2 2012
Comparative Analysis by Mid Clinical Stage Development, H2 2012
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H2 2012
Products under Development by Companies, H2 2012
Products under Investigation by Universities/Institutes, H2 2012
Novogen Limited, H2 2012
Novocell, Inc., H2 2012
Bioo Therapeutics, H2 2012
Assessment by Monotherapy Products, H2 2012
Assessment by Stage and Route of Administration, H2 2012
Assessment by Stage and Molecule Type, H2 2012

LIST OF FIGURES

Number of Products under Development for Ageing, H2 2012
Products under Development for Ageing – Comparative Analysis, H2 2012
Products under Development by Companies, H2 2012
Products under Investigation by Universities/Institutes, H2 2012
Mid Clinical Stage Products, H2 2012
Discovery and Pre-Clinical Stage Products, H2 2012
Assessment by Monotherapy Products, H2 2012
Assessment by Route of Administration, H2 2012
Assessment by Stage and Route of Administration, H2 2012
Assessment by Molecule Type, H2 2012
Assessment by Stage and Molecule Type, H2 2012

Ask Your Question

Ageing – Pipeline Review, H2 2012
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry: